ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Implementing ICH E6 (R3) In A Risk Averse Culture

  Get several pointers on how to facilitate a transition to an agile, multi-faceted, and continuous risk and issue management approach aligned with the Statistical Analysis Plan.

• Providing Drug Supply Support In Complex Environments Through IRT

  Learn how applying predictive data analytics can enable the creation of an ideal supply strategy capable of reducing the need for extra shipments, manual oversight, and supply waste.

• Vendor Selection Bias: Why Structured Decisions Often Fail

  Learn how subtle influences derail decisions and discover proven safeguards that promote transparency, accountability, and shared ownership for better trial outcomes.

• The Strategic Case For RTSM in Phase 1 Trials

  Phase 1 trials demand precision and speed. RTSM delivers real-time control over enrollment, dosing, and supply, reducing risk and enabling adaptive strategies that keep timelines on track.

• How To Differentiate With A Unified eClinical Solution

  Clinical trials are increasingly complex for sites, sponsors, and CROs. In a recent webinar, experts Bill Byrom and Jan Breemans shared how a unified eClinical platform simplifies operations and enhances data quality.

• Measuring The True Patient Experience

  Utilizing the insights covered in this article can inform the design and implementation of cancer trials, ultimately contributing to improved patient care and treatment outcomes.

• Emerging Biopharm Rapidly Sets Up Phase 1 Oncology Trial

  Uncover how an emerging biopharmaceutical company was able to expedite the initiation of a Phase 1 oncology trial for a novel treatment targeting relapsed/refractory multiple myeloma.

• How Vanguard Clinical Harnesses CDMS/EDC For Faster Results

  Uncover how this CRO was able to stay agile by choosing a CDMS/EDC partner that prioritized sponsor needs and streamlined operations to achieve top-tier results swiftly.

• We Need Regulatory Clarity—Not Complexity In Clinical Trial Technology

  The current U.S. deregulatory momentum should not diminish compliance standards but instead serve as a call to streamline and modernize regulatory guidance.

• Software Development's Impact On Future Research And Tech

  Unearth how modern software development in clinical research technology will shape the industry's future.